Abstract

BACKGROUND

The BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) has been authorized for use in children 5 to 11 years of age and adolescents 12 to 17 years of age but in different antigen doses.

Matéria original

Anterior

Outlook of various diagnostics and nanodiagnostic techniques for COVID-19

Próxima

Advances and challenges in using nirmatrelvir and its derivatives against SARS-CoV-2 infection